Azenta, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Azenta closed the sale of B Medical Systems on July 1, 2026 (announced in prior 8-K). Q3 FY2026 continuing operations revenue reached $161M (+12% YoY, +9% organic), with Sample Management Solutions at $88M (+14% YoY) and Multiomics at $73M (+10% YoY). The company recorded a $149M non-cash goodwill impairment ($112.4M Multiomics, $36.6M SMS) in Q2. FY2026 full-year revenue guidance raised to $613–$618M (prior $603–$621M); organic revenue now expected flat to +1% (prior down 2% to +1%). Adjusted EBITDA FY2026 guidance $59–$62M. Company repurchased 2.3M shares for $50M under a $250M program authorized December 2025.
Why this rating
B Medical divestiture removes drag but modest relative to $1B market cap. Guidance raise and organic growth improvement are positive; large impairment and margin compression offset gains. Routine capital management.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.